QPPV.COM KNOWLEDGE ASSESSMENT

21 CFR Part 11: Electronic Records and Electronic Signatures Explained

Test your understanding of the concepts covered by 21 CFR Part 11: Electronic Records and Electronic Signatures in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best distinguishes an electronic record used internally to prepare an FDA submission from an electronic record submitted to FDA?
Question 2 of 10 A computer system is used to prepare a report, but the organisation relies on the final paper report for the regulated activity and the paper report satisfies the applicable predicate-rule requirements. Which conclusion best reflects the article?
Question 3 of 10 A signed validation report is revised after approval. Which control question is most important?
Question 4 of 10 What is the key distinction between authentication and authorisation in a pharmacovigilance system?
Question 5 of 10 Why can metadata be important when preserving a pharmacovigilance electronic record?
Question 6 of 10 Which information must be associated with a signed electronic record under the signature-manifestation concept described in the article?
Question 7 of 10 An organisation keeps a paper case file but performs medical review and regulatory reporting using the electronic case record. What is the most appropriate interpretation?
Question 8 of 10 A company is deciding whether a PDF export, database record or transmitted XML file is the official pharmacovigilance record. What should it do first?
Question 9 of 10 Which capability is most directly relevant to the accurate-and-complete-copy requirement?
Question 10 of 10 Which event is most likely to represent a Part 11 electronic signature rather than an ordinary user interaction?

Select an answer to continue.

QPPV.com